1887

Abstract

In the last decade, the incidence of invasive meningococcal disease (IMD) in Croatia remained stable at approximately 1 case per 100 000 inhabitants, affecting mainly children aged ≤5 years. We report the molecular characterization of meningococci causing IMD occurring from June 2009 to January 2014 in Croatia. Genomic DNA from 50 clinical isolates was analysed for serogroup, multilocus sequence typing and allele type of the two outer membrane protein genes, and the iron-regulated . Furthermore, 22 of them were characterized by using whole-genome sequencing to define the meningococcal vaccine four-component meningococcal serogroup B (4CMenB) antigen genes factor H-binding protein (), heparin-binding antigen () and adhesin A () and the antimicrobial target resistance genes for penicillin (penicillin binding protein 2, ), ciprofloxacin (DNA gyrase subunit A, ) and rifampicin (β-subunit of RNA polymerase, ). The Etest was used to phenotypically determine the antimicrobial susceptibility of isolated meningococci. The main serogroup/clonal complex combinations were MenB cc41/44, MenC/cc11, MenW/cc174 and MenY/cc23. PorA P1.7-2, FetA F5-5 and F1-5 were the most represented through the serogroups. Meningococci with decreased susceptibility to penicillin (38.9 %) and one strain resistant to ciprofloxacin were identified. Forty-two percent of MenB showed the presence of at least one of the 4CMenB vaccine antigens (fHbp, NHBA, NadA and PorA). Our findings highlight the genetic variability of meningococci causing IMD in Croatia, especially for the serogroup B. Molecular-based characterization of meningococci is crucial to enhance IMD surveillance and to better plan national immunization programmes.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000320
2016-09-01
2019-12-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/9/1013.html?itemId=/content/journal/jmm/10.1099/jmm.0.000320&mimeType=html&fmt=ahah

References

  1. Abad R., Medina V., Stella M., Boccadifuoco G., Comanducci M., Bambini S., Muzzi A., Vázquez J. A.. 2016; Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries. PLoS One11:e0150721 [CrossRef][PubMed]
    [Google Scholar]
  2. Bambini S., Piet J., Muzzi A., Keijzers W., Comandi S., De Tora L., Pizza M., Rappuoli R., van de Beek D. et al. 2013; An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One8:e65043 [CrossRef][PubMed]
    [Google Scholar]
  3. Bambini S., De Chiara M., Muzzi A., Mora M., Lucidarme J., Brehony C., Borrow R., Masignani V., Comanducci M. et al. 2014; Neisseria adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol21:966–971 [CrossRef][PubMed]
    [Google Scholar]
  4. Birtles A., Hardy K., Gray S. J., Handford S., Kaczmarski E. B., Edwards-Jones V., Fox A. J.. 2005; Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters. J Clin Microbiol43:6007–6014 [CrossRef][PubMed]
    [Google Scholar]
  5. Boras A., Jeren T., Sacchi C. T., Schmink S., Bozinovic D., Barsic B., Rosenstein N. E., Popovic T.. 2004; Establishment of an active laboratory-based surveillance for bacterial meningitis in Croatia and molecular characterization of Neisseria meningitidis isolates causing meningococcal disease that were collected in the year 2000, the first year of activity. J Clin Microbiol42:1803–1806 [CrossRef][PubMed]
    [Google Scholar]
  6. Bratcher H. B., Corton C., Jolley K. A., Parkhill J., Maiden M. C.. 2014; A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes. BMC Genomics15:1138 [CrossRef][PubMed]
    [Google Scholar]
  7. Brehony C., Hill D. M., Lucidarme J., Borrow R., Maiden M. C.. 2015; Meningococcal vaccine antigen diversity in global databases. Euro Surveill20:30084 [CrossRef][PubMed]
    [Google Scholar]
  8. Bröker M., Emonet S., Fazio C., Jacobsson S., Koliou M., Kuusi M., Pace D., Paragi M., Pysik A. et al. 2015; Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother11:2281–2286 [CrossRef][PubMed]
    [Google Scholar]
  9. Bukovski S., Tambic Andrasevic A., Jelic M., Guzvinec M.. 2013; Nine year history of Neisseria menigitidis group, diagnostic method and antibiotic sensitivity profile. http://emgm.eu/meetings/emgm2013/Abstract_Book_EMGM_2013.pdf
  10. Bukovski S., Jelic M.. 2014; Invasive bacterial disease in Croatia and the role of Neisseria meningitidis. http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf
  11. Corless C. E., Guiver M., Borrow R., Edwards-Jones V., Fox A. J., Kaczmarski E. B.. 2001; Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol39:1553–1558 [CrossRef][PubMed]
    [Google Scholar]
  12. ECDC 2014; Annual Epidemiological Report 2014. Vaccine preventable disease – invasive bacterial disease. http://ecdc.europa.eu/en/publications/Publications/AER-VPD-IBD-2014.pdf
  13. EUCAST 2014; EUCAST Clinical Breakpoints v.4. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/
  14. Frosi G., Biolchi A., Lo Sapio M., Rigat F., Gilchrist S., Lucidarme J., Findlow J., Borrow R., Pizza M. et al. 2013; Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine31:4968–4974 [CrossRef][PubMed]
    [Google Scholar]
  15. Giuliani M. M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A. et al. 2006; A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A103:10834–10839 [CrossRef][PubMed]
    [Google Scholar]
  16. Hong E., Thulin Hedberg S., Abad R., Fazio C., Enríquez R., Deghmane A. E., Jolley K. A., Stefanelli P., Unemo M. et al. 2013; Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin. Antimicrob Agents Chemother57:1961–1964 [CrossRef][PubMed]
    [Google Scholar]
  17. Klismanić Z., Juretić K. B., Tripković I., Barać Juretić K.. 2013; Epidemiological characteristics of invasive meningococcal disease in the Split-Dalmatia County 1996-2010. Acta Clin Croat52:485–491[PubMed]
    [Google Scholar]
  18. Lucidarme J., Comanducci M., Findlow J., Gray S. J., Kaczmarski E. B., Guiver M., Vallely P. J., Oster P., Pizza M. et al. 2010; Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol17:919–929 [CrossRef][PubMed]
    [Google Scholar]
  19. Lucidarme J., Hill D. M., Bratcher H. B., Gray S. J., du Plessis M., Tsang R. S., Vazquez J. A., Taha M. K., Ceyhan M. et al. 2015; Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect71:544–552 [CrossRef][PubMed]
    [Google Scholar]
  20. Simpson J. T., Wong K., Jackman S. D., Schein J. E., Jones S. J., Birol I.. 2009; ABySS: a parallel assembler for short read sequence data. Genome Res19:1117–1123 [CrossRef][PubMed]
    [Google Scholar]
  21. Stephens D. S.. 2009; Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine27:B71–B77 [CrossRef][PubMed]
    [Google Scholar]
  22. Thompson E. A., Feavers I. M., Maiden M. C.. 2003; Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology149:1849–1858 [CrossRef][PubMed]
    [Google Scholar]
  23. Tzanakaki G., Hong E., Kesanopoulos K., Xirogianni A., Bambini S., Orlandi L., Comanducci M., Muzzi A., Taha M. K.. 2014; Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol14:111 [CrossRef][PubMed]
    [Google Scholar]
  24. Törös B., Thulin Hedberg S., Jacobsson S., Fredlund H., Olcén P., Mölling P.. 2014; Surveillance of invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill19:20940 [CrossRef]
    [Google Scholar]
  25. Vogel U., Taha M. K., Vazquez J. A., Findlow J., Claus H., Stefanelli P., Caugant D. A., Kriz P., Abad R. et al. 2013; Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis13:416–425 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000320
Loading
/content/journal/jmm/10.1099/jmm.0.000320
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error